Unknown

Dataset Information

0

Development of orthogonal NISTmAb size heterogeneity control methods.


ABSTRACT: The NISTmAb is a monoclonal antibody Reference Material from the National Institute of Standards and Technology; it is a class-representative IgG1? intended to serve as a pre-competitive platform for harmonization and technology development in the biopharmaceutical industry. The publication series of which this paper is a part describes NIST's overall control strategy to ensure NISTmAb quality and availability over its lifecycle. In this paper, the development of a control strategy for monitoring NISTmAb size heterogeneity is described. Optimization and qualification of size heterogeneity measurement spanning a broad size range are described, including capillary electrophoresis-sodium dodecyl sulfate (CE-SDS), size exclusion chromatography (SEC), dynamic light scattering (DLS), and flow imaging analysis. This paper is intended to provide relevant details of NIST's size heterogeneity control strategy to facilitate implementation of the NISTmAb as a test molecule in the end user's laboratory. Graphical abstract Representative size exclusion chromatogram of the NIST monoclonal antibody (NISTmAb). The NISTmAb is a publicly available research tool intended to facilitate advancement of biopharmaceutical analytics. HMW?=?high molecular weight (trimer and dimer), LMW?=?low molecular weight (2 fragment peaks). Peak labeled buffer is void volume of the column from L-histidine background buffer.

SUBMITTER: Turner A 

PROVIDER: S-EPMC5830496 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Development of orthogonal NISTmAb size heterogeneity control methods.

Turner Abigail A   Yandrofski Katharina K   Telikepalli Srivalli S   King Jason J   Heckert Alan A   Filliben James J   Ripple Dean D   Schiel John E JE  

Analytical and bioanalytical chemistry 20180210 8


The NISTmAb is a monoclonal antibody Reference Material from the National Institute of Standards and Technology; it is a class-representative IgG1κ intended to serve as a pre-competitive platform for harmonization and technology development in the biopharmaceutical industry. The publication series of which this paper is a part describes NIST's overall control strategy to ensure NISTmAb quality and availability over its lifecycle. In this paper, the development of a control strategy for monitorin  ...[more]

Similar Datasets

| S-EPMC5830499 | biostudies-literature
| S-EPMC5830484 | biostudies-literature
| S-EPMC8795419 | biostudies-literature
| S-EPMC3203678 | biostudies-other
| S-EPMC3419455 | biostudies-other
| S-EPMC6152460 | biostudies-literature
| S-EPMC6369574 | biostudies-literature
| S-EPMC1162041 | biostudies-other
| S-EPMC3516299 | biostudies-literature
| S-EPMC6346012 | biostudies-literature